




PHARMACEUTICAL 2023

Traverse Therapeutics Inc.
Rank 330 of 446





PHARMACEUTICAL 2023

Traverse Therapeutics Inc.
Rank 330 of 446



The relative strengths and weaknesses of Traverse Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Traverse Therapeutics Inc. compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 26% points. The greatest weakness of Traverse Therapeutics Inc. is the variable Other Liabilities, reducing the Economic Capital Ratio by 117% points.

The company's Economic Capital Ratio, given in the ranking table, is -32%, being 75% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	486,437
Cost of Goods Sold	7,592
Intangible Assets	145,038
Liabilities, Current	142,163
Liabilities, Non-Current	47,826
Other Assets	32,061
Other Compr. Net Income	-2,345
Other Expenses	15,319
Other Liabilities	439,745
Other Net Income	-11,603
Other Revenues	212,018
Property and Equipment	9,049
Research and Development	235,780
Selling, General and Administrative Expense	220,206

Output Variable	Value in 1000 USD
Assets	672,585
Liabilities	629,734
Expenses	478,897
Revenues	212,018
Stockholders Equity	42,851
Net Income	-278,482
Comprehensive Net Income	-279,654
Economic Capital Ratio	-32%